German firm accused of data breach

It's being called one of the biggest data scandals the German healthcare industry has ever seen. Munich area market research firm Pharmafakt GFD is being accused of selling raw prescription information to drug companies without removing data that can be used to trace identities.

Based on a confession, given “under oath,” and appearing in the magazine Der Spiegel, a former Pharmafakt employee says the datamining company saved data from millions of pharmacy prescriptions, analyzed them and then sold the records to pharma firms, without de-identifying them first.

The research outfit balked at the accusations: “The GFD did not pass on or sell personal data. All data is only used to produce studies,” Pharmafakt GFD manager Dietmar Wassener told the Süddeutsche Zeitung. A state enforcement official who was shown the Pharmafakt data, however, said it seemed authentic.

Clients of Pharmafakt GFD  include several top-10 drug­makers.
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.